Table 5. Criteria recommended by 2017 ATS Guidelines for rapid molecular drug susceptibility testing for rifampin^a.

Criteria	All TB patientsb		DS-TB		Non-MDR/RMP drug resistance		MDR/RMP-R TB		MDR/RMP-R TB vs DS-TB			MDR/RMP-R TB vs non-MDR/RMP drug resistance
	(n=485)	%	(n=306)	%	(n=49)	%	(n=47)	%	OR	(95% CI)	p-value	OR	(95% CI)	p-value
Previous TB treatment	70	14.4	26	8.5	9	18.4	16	34.0	5.39	(2.57–11.3)	<0.001	2.21	(0.83–5.90)	0.112
Born or lived less than one year in higher risk country	428	88.2	264	86.3	43	87.8	45	95.7	2.72	(0.62–11.2)	0.184	3.02	(0.56–16.2)	0.197
Contact of MDR-TB	4	0.8	1	0.3	2	4.1	1	2.1	9.04	(0.54–148.7)	0.123	0.46	(0.03–5.60)	0.548
HIV infection	10	2.1	6	2.0	0	0.0	4	8.5	4.26	(1.06–17.0)	0.04	N/A	N/A	N/A

Abbreviations: ATS, American Thoracic Society; DS, drug-susceptible; HIV, human immunodeficiency virus; MDR, multidrug resistant; N/A, not applicable; R, resistance, RMP, rifampin; TB, tuberculosis

^a Rapid molecular drug susceptibility testing for rifampin by drug resistance pattern (A) and multivariable analyses comparing MDR/RMP-R TB with drug susceptible TB (B) and non-MDR/RMP drug resistant TB (C)

^b TB incidence of ≥20/100,000 or primary MDR prevalence of ≥2%